The Daily Californian writes, “The U.S. Patent and Trademark Office issued UC Berkeley its fourth patent for CRISPR Cas-9, a revolutionary gene-editing technology, April 23, allowing the university’s CRISPR Cas-9 patent portfolio to cover even more uses of the technology. This new patent, 10,266,850, is co-owned, belonging to the university, the University of Vienna and professor Emmanuelle Charpentier of the Max Planck Institute for Infection Biology, and complements three previous patents.”

Referencing client The University of California, Berkeley, Director Eldora L. Ellison, Ph.D. is quoted in the coverage, “We are very pleased at the progress we’re making with the issuance of this patent and will continue to promote the intellectual property of the Doudna-Charpentier team’s CRISPR-Cas9 invention. Today’s patent further builds on the numerous CRISPR-Cas9 applications in UC’s portfolio and will support the university’s commitment to utilizing the genome editing technology for the benefit of our society.”